Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564497 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 491
- Enrollment target
NCT02564497 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 491 participants.
The verdict
NCT02564497, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 491 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the Pharmacokinetics (PK) of Process E belatacept relative to Process C belatacept in Healthy subjects
Interventions
- BIOLOGICAL Process E Belatacept
- BIOLOGICAL Process C Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2015-10-02 |
| Est. Completion | 2017-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564497
The ClinicalTrials.gov registry entry for NCT02564497 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 491 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Process E Belatacept is the first listed.
NCT02564497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02564497 about?
NCT02564497 is a clinical study titled "A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C". The purpose of the study is to compare the Pharmacokinetics (PK) of Process E belatacept relative to Process C belatacept in Healthy subjects
What is the current status of trial NCT02564497?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 491 participants. The study started on 2015-10-02. Estimated completion is 2017-01-27.
What interventions are being tested in trial NCT02564497?
The interventions under investigation include: Process E Belatacept (BIOLOGICAL), Process C Belatacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT02564497?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.